OR WAIT null SECS
August 26, 2021
Eli Lilly and Company and industry partners, including Ziath, are focused on speeding up the drug discovery process with a fully automated lab.
BioMed X has partnered with Janssen to start two new research programs for autoimmune diseases and drug delivery.
August 25, 2021
NGM Biopharmaceuticals has disclosed a fourth antibody drug candidate, NGM831, for development into an oncology therapeutic.
Pfizer’s proposed $2.26-billion acquisition of Trillium Therapeutics will add next-generation hematology-targeted immuno-therapeutics to its oncology pipeline.
August 24, 2021
FDA’s draft guidance provides recommendations for how to include bioequivalence information in ANDAs and ANDA supplements.
HHS Public Health and a team of medical experts recommend that COVID-19 vaccine booster shots will soon be necessary.
FDA approved the Pfizer-BioNTech COVID-19 vaccine, which will be marketed as Comirnaty.
August 20, 2021
Novartis' Cosentyx has been granted further approval from the China National Medical Products Administration for use in pediatric patients.
FDA granted orphan drug designation to Paratek Pharmaceuticals for NUZYRA (omadacycline), an investigational antibiotic.
Bristol Myers Squibb has exercised the option to in-license an immune-modulating drug candidate developed by Exscientia.